# Multinational randomised controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritis

Submission date Recruitment status Prospectively registered 09/05/2002 No longer recruiting [ ] Protocol [ ] Statistical analysis plan Overall study status Registration date 09/05/2002 Completed [X] Results [ ] Individual participant data Last Edited Condition category Musculoskeletal Diseases 15/11/2013

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Mr Sean Curtis

#### Contact details

Merck & Co Inc 126 E Lincoln Avenue Rahway United States of America NJ 07065

# Additional identifiers

Protocol serial number 025

# Study information

Scientific Title

Study objectives

Not provided at time of registration

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Each site received the approval of its Ethics Review Committee or Institutional Review Board to perform the study.

## Study design

Randomised controlled trial

# Primary study design

Interventional

# Study type(s)

**Treatment** 

### Health condition(s) or problem(s) studied

Rheumatoid arthritis

#### **Interventions**

- 1. Etoricoxib 90 mg once daily, naproxen 500 mg twice daily
- 2. Placebo for 12 weeks

#### Intervention Type

Drug

#### Phase

**Not Specified** 

# Drug/device/biological/vaccine name(s)

Etoricoxib, naproxen

#### Primary outcome(s)

Not provided at time of registration

# Key secondary outcome(s))

Not provided at time of registration

#### Completion date

01/06/2000


# **Eligibility**

#### Key inclusion criteria

- 1. Patients with rheumatoid arthritis
- 2. Aged greater than or equal to 18 years

#### Participant type(s)

Patient					
<b>Healthy volunteers allowed</b> No					
<b>Age group</b> Adult					
<b>Lower age limit</b> 18 years					
Sex All					
<b>Key exclusion criteria</b> Does not match inclusion criteria					
<b>Date of first enrolment</b> 01/11/1999					
Date of final enrolment 01/06/2000					
Locations					
Countries of recruitment United Kingdom					
United Kingdom					
United Kingdom Argentina					
United Kingdom Argentina Australia					
United Kingdom Argentina Australia Austria					
United Kingdom Argentina Australia Austria Brazil					
United Kingdom  Argentina  Australia  Austria  Brazil  Canada					
United Kingdom Argentina Australia Austria Brazil Canada Chile					
United Kingdom  Argentina  Australia  Austria  Brazil  Canada  Chile  Colombia					
United Kingdom  Argentina  Australia  Austria  Brazil  Canada  Chile  Colombia  Costa Rica					
United Kingdom  Argentina  Australia  Austria  Brazil  Canada  Chile  Colombia  Costa Rica  France					



Israel

Italy

Lithuania

New Zealand

Mexico

Реги

Romania

Singapore

Slovenia

South Africa

Funder(s)

Funder type

# Industry

#### Funder Name

Merck & Co Inc (USA)

# Alternative Name(s)

Merck & Co., Inc., Merck & Co.

# **Funding Body Type**

Government organisation

# Funding Body Subtype

For-profit companies (industry)

#### Location

United States of America

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	22/05/2002		Yes	No